X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (119) 119
Publication (16) 16
Newspaper Article (14) 14
Book Review (12) 12
Book Chapter (5) 5
Book / eBook (3) 3
Conference Proceeding (3) 3
Dissertation (3) 3
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (65) 65
humans (57) 57
male (37) 37
female (35) 35
urology & nephrology (35) 35
middle aged (29) 29
aged (21) 21
risk factors (19) 19
adult (16) 16
hypertension (16) 16
mortality (15) 15
nephrology (15) 15
risk (14) 14
abridged index medicus (12) 12
medicine, general & internal (11) 11
treatment outcome (10) 10
analysis (9) 9
clinical trials (9) 9
hemodialysis-patients (9) 9
phosphate binder (9) 9
time factors (9) 9
blood pressure (8) 8
chronic kidney-disease (8) 8
end-stage renal disease (8) 8
ferric compounds - therapeutic use (8) 8
glomerular-filtration-rate (8) 8
kidney failure, chronic - therapy (8) 8
outcomes (8) 8
renal dialysis (8) 8
trial (8) 8
cohort studies (7) 7
creatinine (7) 7
diabetes (7) 7
health aspects (7) 7
kidney diseases (7) 7
pharmacology & pharmacy (7) 7
progression (7) 7
prospective studies (7) 7
surgery (7) 7
adults (6) 6
aged, 80 and over (6) 6
anemia (6) 6
article (6) 6
cardiovascular diseases (6) 6
care and treatment (6) 6
diagnosis (6) 6
esrd (6) 6
ferric citrate (6) 6
follow-up studies (6) 6
methods (6) 6
patients (6) 6
peripheral vascular disease (6) 6
population (6) 6
retrospective studies (6) 6
young adult (6) 6
albuminuria (5) 5
biomarkers - blood (5) 5
blood pressure - physiology (5) 5
cardiac & cardiovascular systems (5) 5
chronic kidney disease (5) 5
diabetes mellitus, type 2 - complications (5) 5
dialysis (5) 5
double-blind method (5) 5
hypertension - physiopathology (5) 5
iron (5) 5
management (5) 5
medicine and health sciences (5) 5
nephropathy (5) 5
neurosciences (5) 5
prevalence (5) 5
prevention (5) 5
proteinuria (5) 5
renal function (5) 5
renal insufficiency, chronic - physiopathology (5) 5
renal-disease (5) 5
research (5) 5
safety (5) 5
severity of illness index (5) 5
angiotensin ii type 1 receptor blockers - therapeutic use (4) 4
animals (4) 4
antihypertensive agents - therapeutic use (4) 4
association (4) 4
cardiovascular outcomes (4) 4
chelating agents - therapeutic use (4) 4
chronic kidney failure (4) 4
clinical trial (4) 4
complications and side effects (4) 4
diabetes mellitus, type 2 - drug therapy (4) 4
diabetes mellitus, type 2 - physiopathology (4) 4
disease (4) 4
drug therapy, combination (4) 4
elevated ferritin (4) 4
failure (4) 4
glomerular filtration rate (4) 4
hematinics - administration & dosage (4) 4
hyperphosphatemia (4) 4
hypertension - drug therapy (4) 4
irbesartan (4) 4
kidney - physiopathology (4) 4
kidney failure, chronic - complications (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Seminars in Dialysis, ISSN 0894-0959, 07/2016, Volume 29, Issue 4, pp. 309 - 311
Dialysis patients have absolute and functional iron deficiencies. Traditionally, oral iron preparations have been insufficient to maintain iron stores to... 
FERRIC CITRATE | TRIAL | ESRD | PHOSPHORUS | DIALYSIS PATIENTS | EFFICACY | PHOSPHATE BINDER | ELEVATED FERRITIN | HEMODIALYSIS-PATIENTS | GLUCONATE | UROLOGY & NEPHROLOGY | Iron - administration & dosage | Humans | Nephrology - methods | Hematinics - administration & dosage | Anemia, Iron-Deficiency | Iron - blood | Renal Dialysis | Phosphates | Hemoglobin | Biological products | Index Medicus
Journal Article
by Bohula, Erin A and Scirica, Benjamin M and Inzucchi, Silvio E and Inzucchi, Silvio and McGuire, Darren K and Keech, Anthony C and Keech, Anthony and Smith, Steven R and Smith, S and Kanevsky, Estella and Murphy, Sabina A and Leiter, Lawrence A and Dwyer, Jamie P and Dwyer, Jamie and Corbalan, Ramon and Hamm, Christian and Kaplan, Lee and Nicolau, Jose Carlos and Ophuis, Ton Oude and Ray, Kauski and Ray, Kausik K and Ruda, Mikhail and Spinar, Jindrich and Patel, S and Patel, R and Patel, Tushar and Miao, Wenfeng and Perdomo, Carlos and Francis, Bruce and Dhadda, Shobha and Bonaca, Marc P and Ruff, Christian T and Sabatine, Marc S and Wiviott, Stephen D and Satlin, Andrew and Brown, Conville and Brown, J and Budaj, Andrzej and Garcia-Castillo, Armando and Gupta, N and Gupta, Milan and Oude Ophuis, Ton and Weissman, Neil and White, Harvey D and White, A and White, J and Amerena, J and Arstall, M and Colquhoun, D and Jayasinghe, R and Lee, A and Lee, J and Lehman, R and Moses, R and Proietto, J and Purnell, P and Waites, J and Blombery, P and Cross, D and Worthley, M and d'Emden, M and Selvanayagam, J and Oqueli, RE and Whelan, A and Garrahy, P and de Looze, F and Ninio, D and Horowitz, J and William, M and Suranyi, M and Wittert, G and Le May, M and Pandey, AS and Vizel, S and Labonte, R and Beaudry, Y and Fortin, C and Bell, A and Kouz, S and St-Amour, É and Bata, I and St Maurice, F and Chehayeb, R and Constance, C and Wong, G and Hess, A and Liutkus, J and Poirier, P and Teitelbaum, I and Berlingieri, J and Cha, J and Hartleib, M and Heffernan, M and Twum-Barima, D and Pandith, V and Aronson, R and Goldenberg, R and Ajala, B and Jain, A and Ross, S and ... and CAMELLIA-TIMI61 Steering Comm and CAMELLIA-TIMI 61 Steering Committee Investigators
The Lancet, ISSN 0140-6736, 11/2018, Volume 392, Issue 10161, pp. 2269 - 2279
There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has... 
LIFE-STYLE INTERVENTION | MEDICINE, GENERAL & INTERNAL | THERAPY | LIRAGLUTIDE | REDUCTION | CARDIOVASCULAR OUTCOMES | WEIGHT-LOSS | BARIATRIC SURGERY | FOLLOW-UP | ASSOCIATION | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Overweight - complications | Atherosclerosis - drug therapy | Double-Blind Method | Obesity - complications | Humans | Middle Aged | Diabetes Mellitus, Type 2 - prevention & control | Prediabetic State - prevention & control | Body Weight - drug effects | Atherosclerosis - complications | Male | Prediabetic State - complications | Weight Loss - drug effects | Appetite Depressants - therapeutic use | Prediabetic State - drug therapy | Remission Induction | Diabetes Mellitus, Type 2 - blood | Benzazepines - therapeutic use | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Prevention | Clinical trials | Obesity | Analysis | Diabetic retinopathy | Heart attacks | Body weight | Cardiovascular disease | Diabetic neuropathy | Body weight loss | Risk factors | Body mass index | Randomization | Hyperglycemia | Vascular diseases | Motivation | Atherosclerosis | Hemoglobin | Remission | Diabetes mellitus (non-insulin dependent) | Appetite | Hypertension | Serotonin | Complications | Diabetes mellitus | Weight loss | Health risks | FDA approval | Hypoglycemia | Metabolism | Risk analysis | Patients | Disease control | Disease prevention | Weight control | Statistical models | Arteriosclerosis | Coronary vessels | Microvasculature | Lifestyles | Gastrointestinal surgery | Diabetes | Health risk assessment | Long-term effects | Index Medicus | Abridged Index Medicus
Journal Article
Kidney International, ISSN 0085-2538, 06/2018, Volume 93, Issue 6, pp. 1397 - 1408
Individuals with chronic kidney disease are at increased risk of premature cardiovascular disease. Among them, many with elevated low-density lipoprotein... 
alirocumab | PCSK9 | chronic kidney disease | impaired renal function | LDL-C | safety | C-REACTIVE PROTEIN | RANDOMIZED CONTROLLED-TRIALS | LDL-CHOLESTEROL | METAANALYSIS | SUBTILISIN/KEXIN TYPE 9 | CARDIOVASCULAR-RISK PATIENTS | INHIBITOR ALIROCUMAB | STATIN THERAPY | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | UROLOGY & NEPHROLOGY | POOLED ANALYSIS | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Renal Insufficiency, Chronic - complications | Hypercholesterolemia - drug therapy | Clinical Trials, Phase III as Topic | Cholesterol, LDL - blood | Female | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Kidney - physiopathology | Hypercholesterolemia - blood | Glomerular Filtration Rate | Down-Regulation | Risk Factors | Treatment Outcome | Biomarkers - blood | Proprotein Convertase 9 - metabolism | Renal Insufficiency, Chronic - physiopathology | Anticholesteremic Agents - adverse effects | Randomized Controlled Trials as Topic | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypercholesterolemia - diagnosis | Hypercholesterolemia - complications | Aged | Hypertension | Lipoproteins (low density) | Renal function | Kidneys | Epidermal growth factor receptors | Lipids | Triglycerides | Apolipoproteins | Low density lipoprotein | Cholesterol | Apolipoprotein B | Hypercholesterolemia | Kidney diseases | Safety | Cardiovascular diseases | Drug dosages | Statins | Index Medicus
Journal Article
Journal Article
Journal Article
Journal of the American Society of Nephrology, ISSN 1046-6673, 02/2015, Volume 26, Issue 2, pp. 493 - 503
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2010, Volume 362, Issue 21, pp. 2034 - 2037
To the Editor: In his Perspective article regarding the performance of futile cardiopulmonary resuscitation (CPR), Truog (Feb. 11 issue) 1 calls attention to... 
MEDICINE, GENERAL & INTERNAL | Family | Medical Futility - ethics | Patient Rights | Humans | Cardiopulmonary Resuscitation - ethics | Conflicts of interest | Palliative care | Physicians | Index Medicus | Abridged Index Medicus
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2014, Volume 64, Issue 5, pp. 714 - 722
Background Increased systolic blood pressure variability between outpatient visits is associated with increased incidence of cardiovascular end points.... 
Nephrology | diabetic kidney disease | kidney disease outcomes | Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) | Visit-to-visit variability in blood pressure | systolic blood pressure (SBP) | Reduction of End Points in NonInsulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) | MORTALITY | Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) | ATHEROSCLEROSIS | RISK | MELLITUS | IMPACT | DISEASE | UROLOGY & NEPHROLOGY | ASSOCIATION | PROGRESSION | Kidney - physiology | Prospective Studies | Tetrazoles - pharmacology | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Diabetic Nephropathies - drug therapy | Male | Diabetic Nephropathies - diagnosis | Angiotensin II Type 1 Receptor Blockers - pharmacology | Biphenyl Compounds - therapeutic use | Diabetic Nephropathies - physiopathology | Biphenyl Compounds - pharmacology | Female | Blood Pressure - drug effects | Blood Pressure - physiology | Cardiovascular Diseases - diagnosis | Cardiovascular Diseases - physiopathology | Kidney - drug effects | Double-Blind Method | Treatment Outcome | Office Visits - trends | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - physiopathology | Tetrazoles - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Cohort Studies | Index Medicus
Journal Article